Asymchem Laboratories (Tianjin) Co., Ltd. announced a further grant of 27.83 million H-share restricted Incentive Shares on 8 July 2026 under its existing H Share Restricted Share Scheme. The award price is set at RMB1.00 per share, while the H-shares closed at HK$109.50 on the grant date.
The allocation includes 25,000 shares each to Executive Directors Yang Rui, Zhang Da and Hong Liang, plus 0.57 million shares to other eligible employees. Based on the current share base, each director’s allotment equals approximately 0.09 % of issued H-shares and 0.01 % of total issued shares (excluding treasury shares); the employee tranche represents 2.03 % of issued H-shares and 0.16 % of total issued shares.
All Incentive Shares will be sourced through on-market purchases by the scheme trustee, so no new equity will be issued and existing shareholders will not face dilution.
Vesting will occur in four equal tranches of 25 % each, beginning one year after the initial 12-month holding period from the 8 July 2026 grant date and continuing annually through the fourth year. Every vested batch is subject to an initial three-month lock-up, with the Board reserving the right to impose an additional three-month restriction depending on market conditions.
Actual vesting ratios hinge on corporate and individual performance metrics, notably operating-income growth and net-profit growth. A claw-back framework allows the Board to cancel unvested awards in cases of misconduct, breach of duty, non-compete violations or other specified adverse events.
No financial assistance will be provided to awardees for share purchases. The independent non-executive directors have approved the grants to the three executive directors, who abstained from voting.
Following this issue, Asymchem confirmed that the H Share Scheme Mandate Limit is fully utilised; 2.09 million Incentive Shares previously granted remain outstanding and vested, comprising 1.13 million newly issued shares and 0.96 million shares bought on-market.
Comments